GNRSU Stock Crashes 99.99% on Pink Sheets Exchange May 2026

GNRSU stock has experienced a catastrophic collapse, plummeting 99.99% from $0.15 to just $0.000001 per share on the Pink Sheets (PNK) exchange. The Greenrose Holding Company Inc., a healthcare sector cannabis producer based in Amityville, New York, now trades at penny stock levels with a market cap of only $13. This dramatic decline reflects severe operational and financial distress. The company, which went public in February 2020, cultivates and processes medical cannabis products through its subsidiaries. With only 145 shares trading daily and a previous close of $0.15, GNRSU stock represents one of the most severe equity collapses in recent market history.

GNRSU Stock Price Collapse and Market Conditions

GNRSU stock has become a cautionary tale of market failure. The stock trades at $0.000001, representing a near-total wipeout for shareholders. Trading volume sits at just 145 shares daily, indicating virtually no liquidity. The 52-week high of $0.151 shows how far the stock has fallen in recent months.

The Pink Sheets exchange lists GNRSU as an over-the-counter security with minimal regulatory oversight. This environment makes price discovery nearly impossible. Bid-ask spreads likely exceed 100%, making any exit strategy extremely difficult for remaining shareholders. The company’s enterprise value of $101.4 million stands in stark contrast to its $13 market cap, suggesting massive debt and liabilities.

Financial Metrics Reveal Deep Structural Problems

GNRSU’s financial ratios paint a picture of severe distress. The current ratio of 0.21 indicates the company cannot cover short-term obligations with current assets. Working capital sits at negative $103.4 million, showing the company burns cash faster than it generates it. Debt-to-equity ratio of 1.57 means liabilities exceed shareholder equity by 57%.

The company reports positive earnings metrics on paper, with EPS of $3.097 and net profit margin of 70.6%. However, these figures appear distorted by the microscopic share price and minimal market cap. The price-to-earnings ratio of 0.0000000896 is essentially meaningless. Track GNRSU on Meyka for real-time updates on this distressed security.

Cannabis Industry Headwinds and Operational Challenges

Greenrose operates in the healthcare sector as a drug manufacturer specializing in cannabis products. The company employs 910 full-time workers across its Amityville headquarters and subsidiary operations. However, the cannabis industry faces significant regulatory uncertainty and banking restrictions that limit growth opportunities.

The company’s inventory turnover of 0.83 suggests slow-moving product inventory. Days of inventory outstanding reaches 439 days, meaning products sit for over a year before sale. This ties up massive capital and increases obsolescence risk. Operating margins of 38.7% appear healthy, but cannot offset the company’s structural debt burden and liquidity crisis.

Market Sentiment and Trading Activity

Trading Activity: GNRSU stock shows virtually no trading interest. Daily volume of 145 shares represents a dead market. The 50-day and 200-day moving averages both sit at $0.15, indicating the stock has been in free fall below these technical levels. No institutional investors likely hold positions at these levels.

Liquidation Pressure: The negative working capital of $103.4 million suggests forced asset sales may be underway. Tangible asset value is negative $116.3 million, indicating liabilities exceed all tangible assets. Shareholders face potential dilution or complete wipeout if the company attempts a restructuring or bankruptcy filing. The cash conversion cycle of 403 days shows severe operational inefficiency.

Final Thoughts

GNRSU stock has collapsed 99.99% from $0.15 to $0.000001, indicating fundamental business failure. The company faces potential insolvency with negative working capital of $103.4 million and negative tangible assets of $116.3 million. Trading volume has dried up with only 145 daily shares and a $13 market cap. Despite a B grade from Meyka AI, this distressed security requires extreme caution. The cannabis operations and 910 employees face an uncertain future.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.